|会社名||CRISPR Therapeutics AG （CRISPRセラピュ―ティクス）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Biological Products (No Diagnostic Substances)|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA) which is comprised of a crRNA component and a tracrRNA component either individually or combined together as a single guide RNA. The Company has business operations in London the United Kingdom as well as research and development operations in Cambridge the United States. CRISPRセラピュ―ティクスはスイスのバイオ医薬品企業。ゲノム編集に従事し、遺伝子ベ―スの病気の治療に使用される「CRISPR/Cas9」プラットフォ―ムを開発する。スイス、米国、英国で事業を展開する。「CRISPR」ベ―スの開発をバイエルとバ―テックス・ファ―マシュ―ティカルズと協業する。本社はバ―ゼル。 CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.|
|本社所在地||Baarerstrasse 14 Zug 6300 CHE|
|代表者氏名||Rodger Novak ロジャーノヴァク|
|代表者役職名||Chairman of the Board of Directors President Founder|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Crispr Therapeutics AG revenues decreased 61% to $2.4M. Net loss increased 52% to $66.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 31% to $37.1M (expense) Stock-based Compensation in R&D increase from $3.7M to $8.1M (expense).|
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global 2023/04/06 04:15:46 Benzinga
Cathie Wood -led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attractive in terms of valuations. What Happened: Funds operated by ARK bought shares of Crispr Therapeutics AG (NASDAQ: CRSP ), Intellia Therapeutics Inc (NASDAQ: NTLA ), Verve Therapeutics Inc (NASDAQ: VERV ), Beam Therapeutics Inc (NASDAQ: BEAM ) and Ginkgo Bioworks Holdings Inc (NYSE: DNA ). Also Read: Best Exchange Traded Funds (ETFs) The purchase was conducted via the flagship ARK … Full story available on Benzinga.com
Vertex, CRISPR finish sickle cell candidate application 2023/04/03 12:39:07 Seeking Alpha
Vertex and CRISPR Therapeutics have completed a rolling submission of an application to the FDA for exa-cel for sickle cell disease and beta thalassemia. Read more here.
Vertex Pharmaceuticals Incorporated: Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia 2023/04/03 12:12:00 Finanz Nachrichten
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR The…
BUSINESS WIRE: Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia 2023/04/03 12:00:07 Finanztreff
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023-BOSTON & ZUG, Switzerland --(BUSINESS WIRE)-- 03.04.2023 --Vertex Pharmaceuticals…
CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia 2023/04/03 12:00:00 CRISPR Therapeutics
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- BOSTON and ZUG, Switzerland, April 3, 2023 - CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of the rolling
Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold 2023/03/09 13:50:00 The Motley Fool
Get in on CRISPR Therapeutics before it gets expensive.
CRISPR Therapeutics AG (CRSP) did well last session? 2023/03/08 14:48:00 US Post News
CRISPR Therapeutics AG (NASDAQ:CRSP) marked $47.84 per share on Tuesday, down from a previous closing price of $49.33. While CRISPR Therapeutics AG has underperformed by -3.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CRSP fell by -10.06%, with highs and lows ranging from $86.95 to […]
7 Cathie Wood Stocks for Your March Buy List 2023/03/07 19:48:57 InvestorPlace
Investing in Cathie Wood stocks means directing your money toward innovation. And that means investing heavily in tech, a sector that has been pummeled by interest rates held higher by a Federal Reserve battling runaway inflation. Cathie Wood’s portfolio can be found here and includes hundreds of holdings primarily in tech. Wood’s ARK Investment Management includes several actively managed ETFs that focus on high-growth companies in fields such as genomics, robotics, and fintech. ARK’s most popular funds include the ARK Innovation ETF (NYSEARCA: ARKK ), ARK Next Generation Internet ETF (NYSEARCA: ARKW ), and ARK Genomic Revolution ETF (BATS: ARKG ). Of course, any investor seeking to invest in Cathie Wood stocks could simply establish a position in any of those ETFs. That would be a reasonable method for following her investment methods. However, this list consists of individual stock picks all found within ARK’s respective ETFs. NVDA Nvidia $234.27 TSLA Tesla $189.67 NTLA Intellia Therapeutics $40.51 ADYEY Adyen $14.43 CAT Caterpillar $248.26 CRSP CRISPR $48.18 MGA Magna International $55.59 Cathie Wood Stocks: Nvidia (NVDA) Source: Michael Vi / Shutterstock.com Most investors know Nvidia (NASDAQ: NVDA ) as a leading semiconductor company that designs and manufactures advanced graphics processing units for gaming, data centers, and artificial intelligence.
Baird Starts CRISPR Therapeutics at Neutral 2023/03/06 21:28:05 Investing.com
CRISPR Therapeutics AG (CRSP) Cowen 43rd Annual Healthcare Conference (Transcript) 2023/03/06 20:31:05 Seeking Alpha
CRISPR Therapeutics AG (NASDAQ:NASDAQ:CRSP) Cowen 43rd Annual Healthcare Conference Call March 6, 2023 10:30 AM ETCompany ParticipantsSam Kulkarni - Chief Executive OfficerConference Call…
CRSP, ICPT and PFG are among after hour movers 2022/09/01 22:26:29 Seeking Alpha
Gainers: HashiCorp (HCP) +14%. lululemon athletica (LULU) +10%
Here''s How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today 2022/08/31 21:42:17 Benzinga
CRISPR Therapeutics (NASDAQ: CRSP ) has outperformed the market over the past 5 years by 16.43% on an annualized basis producing an average annual return of 26.37%. Currently, CRISPR Therapeutics has a market capitalization of $5.08 billion. Buying $100 In CRSP: If … Full story available on Benzinga.com
CRISPR Therapeutics to Participate in Upcoming Investor Conferences 2022/08/31 12:00:00 GlobeNewswire
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in September.
5 Top Stocks Cathie Wood Is Selling This Week 2022/08/26 20:53:05 InvestorPlace
Shares of Cathie Wood’s flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ) closed the week down about 2.5%, losing out on earlier gains during the week. However, retail investors haven’t lost hope in ARKK, or Cathie Wood just yet. In the five trading days that ended Aug. 15, investors poured $54.2 million into ARKK, the most in a five-day span since May. The ETF is still down over 50% year-to-date (YTD), even after a significant rally from its June lows. Cathie Wood continues to hold her highest conviction holdings, such as Tesla (NASDAQ: TSLA ) and Teladoc (NYSE: TDOC ). At the same time, she has sold off shares of lower conviction holdings in favor of new names. Let’s get into the details. 5 Stocks That Cathie Wood Sold This Week 1. Signify Health (SGFY) Ark Invest continued its sales of Signify Health (NYSE: SGFY ) for a third straight week. This week, ARKK and the ARK Genomic Revolution ETF (BATS: ARKG ) sold off a total of 3.14 million shares . Earlier this week, it was reported that four companies, including CVS (NYSE: CVS ) and UnitedHealth (NYSE: UNH ), were competing to acquire the healthcare company.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 CRISPRセラピュ―ティクス CRSP CRISPR Therapeutics AG）